Growing community of inventors

Belleserre, France

Pierre Sokoloff

Average Co-Inventor Count = 2.90

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 15

Pierre SokoloffThierry Imbert (1 patent)Pierre SokoloffJean-Pierre Rieu (1 patent)Pierre SokoloffJean-Francois Patoiseau (9 patents)Pierre SokoloffPhilippe Maillos (4 patents)Pierre SokoloffJean-François Patoiseau (1 patent)Pierre SokoloffJean-Louis Vidaluc (2 patents)Pierre SokoloffAgnès Auclair (1 patent)Pierre SokoloffPaul Moser (1 patent)Pierre SokoloffFrédéric Cachoux (1 patent)Pierre SokoloffLudovic Leriche (1 patent)Pierre SokoloffFlorence Cuisiat (0 patent)Pierre SokoloffFrederic Cachoux (0 patent)Pierre SokoloffPaul Moser (0 patent)Pierre SokoloffAgnes Auclair (0 patent)Pierre SokoloffPierre Sokoloff (3 patents)Thierry ImbertThierry Imbert (22 patents)Jean-Pierre RieuJean-Pierre Rieu (14 patents)Jean-Francois PatoiseauJean-Francois Patoiseau (9 patents)Philippe MaillosPhilippe Maillos (4 patents)Jean-François PatoiseauJean-François Patoiseau (2 patents)Jean-Louis VidalucJean-Louis Vidaluc (2 patents)Agnès AuclairAgnès Auclair (1 patent)Paul MoserPaul Moser (1 patent)Frédéric CachouxFrédéric Cachoux (1 patent)Ludovic LericheLudovic Leriche (1 patent)Florence CuisiatFlorence Cuisiat (0 patent)Frederic CachouxFrederic Cachoux (0 patent)Paul MoserPaul Moser (0 patent)Agnes AuclairAgnes Auclair (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Pierre Fabre Medicament (2 from 266 patents)

2. Other (1 from 832,718 patents)


3 patents:

1. 10028948 - Chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder

2. 9381195 - Derivatives of azaindazole or diazaindazole type for treating pain

3. 8546402 - Chromone derivatives, a process for their preparation and their therapeutic applications

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/10/2025
Loading…